Low expression of BMPRIB indicates poor prognosis of breast cancer and is insensitive to taxane-anthracycline chemotherapy.
Low expression of BMPRIB indicates poor prognosis of breast cancer and is insensitive to taxane-anthracycline chemotherapy.
复制标题
BMPRIB 低表达表明乳腺癌预后不良，并且对紫杉烷-蒽环类化疗不敏感。
DOI：
10.18632/oncotarget.6613
复制
发表时间：
2016-01-26
期刊：
影响因子：
--
通讯作者：
Ma Y
中科院分区：
文献类型：
--
作者：
Dai K;Qin F;Zhang H;Liu X;Guo C;Zhang M;Gu F;Fu L;Ma Y
骨形态发生蛋白受体IB（BMPRIB）是一种成骨因子，其在乳腺癌中的作用目前尚不清楚。在这里介绍的临床研究中，涉及368例浸润性导管癌（IDC）患者的队列，我们确定了BMPR B低表达的患者预后不良，特别是在管腔B亚型。我们还首次提供了低水平的BMPRIB是乳腺癌患者发生骨转移的促进因素，而不是肺、肝或脑转移的促进因素。我们首次报道了BMPRIB高表达的患者通过回顾性分析168例接受TE（紫杉烷和蒽环类）方案治疗的患者表现出良好的预后。BMPRIB高表达的患者对TE方案的敏感性更高。总之，我们的研究得出结论，BMPRIB的低表达表明乳腺癌预后不良，并且对紫杉烷-蒽环类化疗不敏感。我们的研究结果也为帮助临床医生在精准医学时代通过BMPRIB改善TE方案患者的识别奠定了基础。
Bone morphogenetic protein receptor type IB (BMPRIB) is one osteogenesis factor, which function in breast cancer has been rarely explored until recently. In the clinical study presented here, involving a cohort of 368 invasive ductal carcinoma (IDC) patients, we identified that patients with low expression of BMPRIB exhibited poor prognosis, especially in the luminal B subtype. We also provided the first piece of evidence that low level of BMPRIB was a promoting factor for breast cancer patients to develop bone metastasis, but not lung, liver or brain. The first of its kind, we reported that patients with high expression of BMPRIB exhibited favorable prognosis by a retrospective analysis consisting of 168 patients treated with TE (taxane and anthracycline) regimens. And the patients with high expression of BMPRIB were more sensitive to TE regimens in the detection of 32 paired pre-neoadjuvant and post-neoadjuvant specimens. Overall, our study concluded that low expression of BMPRIB indicated poor prognosis of breast cancer and was insensitive to taxane-anthracycline chemotherapy. Our findings also lay a foundation to help clinicians improve identification of patients for TE regimens by BMPRIB in the era of precision medicine.